CD13 as a potential theranostic target for prostate-specific membrane antigen-negative prostate cancer and first-in-human study of [18F]AlF-CD13-L1 PET/CT imaging.
Purpose: Approximately 10% of prostate cancer (PCa) are prostate-specific membrane antigen (PSMA)-negative, leading to blind spots in PSMA-based diagnosis. This study aimed to identify a potential target for PSMA-negative PCa and preliminarily evaluate the feasibility of using radionuclide probe tar...
| Published in: | European Journal of Nuclear Medicine & Molecular Imaging Vol. 52; no. 8; pp. 2826 - 2841 |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Journal Article |
| Published: |
Springer Nature
Jul2025
|
| Online Access: | View this record in EBSCOhost |